From Banking to Biotech: Renée Aguiar-Lucander, CEO of Calliditas, on Rare Disease Innovation

Biotech 2050 Podcast

Synopsis: Renée Aguiar-Lucander, CEO of Calliditas Therapeutics, appears on this insightful episode of Biotech 2050 with host Rahul Chaturvedi. Renée shares her unconventional journey from investment banking to biotech leadership, underscoring the crucial role of capital markets and regulatory strategies. The discussion explores the unique challenges of developing treatments for rare diseases, strategic decisions on indication selection, and the complexities of managing a global team. Highlighting the importance of continuous learning and curiosity, Renée provides invaluable insights into navigating the fast-paced biotech industry. Tune in to discover the strategic and operational nuances of leading a successful biotech company in today's dynamic environment. Biography: CEO since 2017. Before joining Calliditas, Renée Aguiar-Lucander was a Partner and COO of Omega Fund Management, an international venture capital company focused on investments within the life science sector. Before that, she served as a Partner in the venture capital group 3i Group plc in London, where she managed the publicly quoted assets and was co-head of the global healthcare and technology portfolio. Prior to this, Renée Aguiar-Lucander was the European Group Head and Managing Director at a global investment bank and has more than 12 years’ experience in corporate finance. Prior to her career in investment banking, she was the Head of European Sales and Marketing in a company focused on the sale of software for financial services. Renée took up BA in Finance from Stockholm School of Economics and finished her MBA from INSEAD.